1 (Image 01)
Chemical structure of ethynodiol diacetate with molecular weight 384.51.*
Zovia 1/35 Kit
Product Images NDC 75907-087
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Zovia 1/35 (NDC 75907-087). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Dr. Reddy�s Laboratories Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
2 (Image 02)
Chemical structure of ethinyl estradiol, labeled with its molecular weight (M.W.=296.41). The diagram shows the molecular arrangement including hydroxyl (OH) groups and the ethynyl group characteristic of ethinyl estradiol.*
14 (Image 03)
Data table presenting the percentage of women experiencing unintended pregnancy within the first year of using various contraceptive methods under typical and perfect use conditions, along with the percentage of women continuing use at one year, in the United States. Methods include chance, spermicides, periodic abstinence, withdrawal, barrier methods, pills, IUDs, injections, implants, and sterilization, with detailed breakdowns and continuation rates.*
3 (Image 04)
A warning text panel detailing the increased risk of serious cardiovascular side effects from oral contraceptive use associated with cigarette smoking. It highlights that the risk escalates with age and heavy smoking (15 or more cigarettes per day), especially in women over 35, advising women using oral contraceptives not to smoke.*
4 (Image 05)
A bar chart illustrating mortality rates (number of deaths per 100,000 woman-years) across different age groups (15-24, 25-34, 35-44, 45+) comparing ever-users and controls of Zovia 1/35, segmented by smoking status (non-smokers and smokers). Mortality rates increase with age, with the highest rate among ever-users who are smokers aged 45 and older.*
5 (Image 06)
A data table showing the annual number of birth-related or method-related deaths associated with fertility control methods per 100,000 nonsterile women, categorized by age groups (15-19 through 40-44). Different fertility control methods listed include no fertility control, oral contraceptives (nonsmoker and smoker), IUD, condom, diaphragm/spermicide, and periodic abstinence. Death types are noted as birth-related or method-related.*
7 (Image 07)
A boxed warning text on oral contraceptive use highlighting the increased risk of serious cardiovascular adverse effects from cigarette smoking, especially in women over 35 years old or heavy smokers (15+ cigarettes per day). It advises women using oral contraceptives to avoid smoking.*
15 (Image 08)
A data table presenting the percentage of women experiencing unintended pregnancy and continuation rates at one year for various contraceptive methods during typical and perfect use in the United States. It includes methods such as chance, spermicides, periodic abstinence, withdrawal, various barrier methods, pills, IUDs, injections, implants, sterilization, and emergency contraceptive pills, with additional notes on lactational amenorrhea method effectiveness.*
8 (Image 09)
A warning text panel stating that cigarette smoking increases the risk of serious adverse effects on the heart and blood vessels from oral contraceptive use, especially in women over 35 and heavy smokers (15 or more cigarettes per day). It advises women who use oral contraceptives not to smoke.*
9 (Image 10)
A data table showing the annual number of birth-related or method-related deaths per 100,000 nonsterile women by age group and fertility control method. Methods listed include no fertility control, oral contraceptives (for nonsmokers and smokers), intrauterine device (IUD), condom, diaphragm/spermicide, and periodic abstinence, with death rates given for age ranges from 15-19 through 40-44.*
10 (Image 11)
Zovia 1/35 kit blister card containing 28 tablets labeled with days of the week for daily use. The card shows four rows corresponding to weeks, with pale pink active tablets and white inactive tablets. Instructions indicate taking pills from left to right each week, and the label includes the active ingredients Ethynodiol Diacetate and Ethinyl Estradiol at 1 mg and 0.035 mg respectively, distributed by Dr. Reddy's Laboratories Inc.*
11 (Image 12)
Illustration showing the week-by-week pill-taking instructions for Zovia 1/35 Ethynodiol Diacetate and Ethinyl Estradiol Tablets kit. It depicts a hand placing a day label sticker on the kit and indicates to start from Sunday or the first day of the period. The diagram shows a pill tray organized in four weeks with pale pink active tablets and white inactive tablets, with an arrow directing pill intake from left to right each week.*
12 (Image 13)
13 (Image 14)
Packaging label for Zovia 1/35 (Ethynodiol Diacetate and Ethinyl Estradiol Tablets, USP) kit by Dr. Reddy's Laboratories Inc. The label indicates 6 blister cards of 28 tablets each (21 active pale pink tablets and 7 inert white tablets). The label includes dosage directions, storage instructions, and warnings that the product is intended to prevent pregnancy and does not protect against HIV or other sexually transmitted diseases.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
